Article By:
ChinaBio® Today
Saturday, December 16, 2017 5:21 PM EDT
Fosun Pharma obtained China rights to tenapanor, an Ardelyx treatment for irritable bowel syndrome with constipation (IBS-C), in a $125 million agreement. Tenapanor is also expected to treat hyperphosphatemia related to chronic kidney disease.